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Summary Ras oncogene activation is a key genetic event in several types of human cancer, making its signal pathways an ideal target for
novel therapies. We previously showed that expression of mutant ras sensitizes human thyroid epithelial cells to induction of cell death by
treatment with phorbol 12-myristate 13-acetate (PMA) and other phorbol esters. We have now investigated further the nature and mechanism
of this cell death using both primary and cell line models. The cytotoxic effect of PMA could be bocked by bisindolylmaleimide (GF 109203X),
a well-characterized inhibitor of c and n protein kinase C (PKC) isoforms, and by prior down-regulation of PKC, indicating that it is mediated
by acute stimulation, rather than down-regulation. Westem analysis identified two candidate isoforms - a and E - both of which showed PMA-
induced subcellular translocation, either or both of which may be necessary for PMA-induced cell death. Immunofluorescence showed that
PMA induced a rapid nuclear translocation of p42 MAP kinase of similar magnitude in the presence or absence of mutant ras expression. Cell
death exhibited the microscopic features (chromatin condensation, TdT labelling) and DNA fragmentation typical of apoptosis but after a
surprising lag (4 days). Taken together with recent models of ras-modulated apoptosis, our data suggest that activation of the MAPK pathway
by PMA tips the balance of pro- and anti-apoptotic signals generated by ras in favour of apoptosis. The high frequency of ras mutations in
some cancers, such as cancer of the pancreas, which are refractory to conventional chemotherapy, together with the potential for stimulating
PKC by cell-permeant pharmacological agents, makes this an attractive therapeutic approach.
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Point mutation of a member of the ras oncogene family (H-ras.
Ki-ras. or N-ras) occurs at high frequency in several types of
human epithelial tumour. notably those ofcolon (Bos et al. 1987).
pancreas (Almoguera et al. 1988) and thyroid (Lemoine et al.
1989). and. indeed. at least in these types oftumours. ras mutation
appears to be the initiating molecular event (Lemoine et al. 1989:
Suarez et al. 1990). This is supported. firstly. by the occurrence of
mutation in the earliest tumours available for analysis (Lemoine et
al. 1989: Suarez et al. 1990: Namba et al, 1990) and. secondly. by
the ability to induce in vitro a phenotype consistent with the
benign tumour in vivo by introduction of a mutant ras gene into
primary thyroid epithelial cells (Bond et al. 1992).
Using this model. we investigated the effect of phorbol 12-
myristate 13-acetate (PMA) on mutant ras-induced growth of
primary thyroid cells. initially anticipating a synergistic action.
However. PMA failed to stimulate growth but instead killed cells
expressing mutant ras. while having no effect on normal cells
(Bond et al. 1992). To exclude the possibility that this differential
toxicity simply reflected the much higher proliferative rate of
primary cells expressing mutant H-ras (Bond et al. 1992). a series
ofthyroid cell lines was developed that expresses a mutant ras gene
under the control of a zinc-inducible metallothionein promoter
(Dawson et al. 1993). Treatment with PMA ofa representative cell
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line. R18. resulted in massive cell death when ras expression was
induced but was without effect in uninduced cultures. thereby
demonstrating that the toxic effect was independent ofcell prolifer-
ation (Dawson et al. 1993).
Given the potential therapeutic implications of these findings.
we have now investigated the mechanism of PMA-induced toxi-
city further. in particular to distinguish whether the toxic effect is a
result of stimulation or of down-regulation of protein kinase C
(PKC). to identify the role ofspecific PKC isoforms and to analyse
the 'mode' of PMA-induced cell death. The results support the
potential value of PKC stimulators as a 'rational' chemotherapy
for cancers expressing mutant ras.
MATERIALS AND METHODS
Chemicals and reagents
Monoclonal antibodies against PKC a D yP . 6. 0. T. A were
obtained from Transduction Laboratories (Lexington. USA).
Polyclonal anti-PKC 4 was purchased from Gibco. polyclonal
anti-p42 MAPK from Santa Cruz Biotechnology. GF 109203X
(Calbiochem-Novobiochem) and PMA (Sigma) were dissolved in
dimethyl sulphoxide (DMSO) at stock concentrations of 1 mai and
1 mg ml respectively. GF 109203X was used at a final concentra-
tion of 4gM and PMA at 1 gg ml' (l.6 gM). Etoposide (VP-16-
213: Bristol Myers Pharmaceuticals. Syracuse. NY. USA) was
diluted from a 34 mm stock in the appropriate culture medium as
indicated.
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Cells and culture conditions
Primary thyroid culture
Monolayercultures ofhuman thyroid follicular epithelial cells were
prepared as described previously (Williams et al, 1987) by protease
digestion and mechanical disaggregation of fresh surgical samples
of normal thyroid tissue and cultured in a mixture of Dulbecco's
modified Eagle medium/Ham's F12/MCDB104 (2:1:1) supple-
mented with 10% fetal calfserum (FCS. Imperial Laboratories).
R18 cell line
The human thyroid cell line RI8 expressing mutant H-ras (X-al12)
underthe control ofa zinc-inducible metallothionein promoter was
derived from an SV4O-immortalized human thyroid cell line
(Dawson et al. 1993). Cells were grown in RPMI 1640 medium
(Flow Laboratories) supplemented with 10% FCS and0.4 mg ml-'
G418 (Gibco). Mutant ras expression was induced by the addition
of Zn>+ (as zinc sulphate: Sigma) to the medium. at the indicated
concentrations.
Colony assays
Primary epithelial cells
Thyroid follicular cells were plated at 5 x I0 cells per 60-mm dish
and allowed to attach for48 h before introduction ofmutant human
H-ras by infection with the retroviral vector N-CRIP-DOEJ
(Compere et al. 1989) in the presence of polybrene (8gg ml-') as
A
described (Bond et al. 1992). Cultures were re-fed with non-selec-
tive medium 24 h after infection and maintained for 3 days to
permit viral integration and expression. They were then passaged
into three 60-mm dishes with medium containing 10% FCS and
0.4 mg ml' G418. with or without the addition of bisindolyl-
maleimide GF 109203X 4gM, PMA 1 jg ml' or DMSO carrier
control (up to 5 jl ml-1) as appropriate. Ten days later. cells were
fixed with methanol-acetic acid (3:1). stained with Giemsa and the
number ofcolonies counted.
R18 cell line
Cells were plated at clonal density (approximately 3 x 10 cells
per 60-mm dish) in RPMI. containing 10%c dialysed FCS. and left
for 24 h to attach before the addition of 50 jm Zn2+ to one-half of
the plates. The cells were kept for 48 h to permit induction of
mutant ras before PMA 1 jg ml' and GF 109203X 4 pm or
DMSO carrier control were added as specified. Effects on colony
formation were assessed by fixing and staining dishes after a
period of 10 days.
All colony-forming experiments were performed at least four
times.
Assay of cell growth and survival in semi-confluent
cultures
R18 cells were plated at 5xI04 per 60-mm dish and incubated for
24 h. after which 75 jiM Zn>+ was added to one-half of the plates.
B
Figure 1 Colony growth ofthyroid folicularepitheliai cells infected with the retroviral vectorV1-CRIP-DOEJ coding for mutant H-ras. (A) Untreated ras-
expressing colonies, (B) treated with GF 109203X alone, (C) PMA alone and (D) simultaneous treatment with PMA and GF 109203X
BritishJournal ofCancer(1998) 78(5), 641-651 0 CancerResearch Campaign 1998Mutantras as a therapeutic target 643
Forty-eight hours later. cultures were treated with PMA 1 gg ml-'
and/or GF 109203X 4 gm as described above. After a further 5
days. dishes were trypsinized and the number of surviving cells
estimated using a haemocytometer.
Western blot analysis
For Western analysis of PKC isoform expression. R18 cells were
seeded at 106 per 150-mm dish and incubated for 5 days before the
preparation of protein fractions. When appropriate. cells were
treated with PMA I gg ml' for a period of 30min before
processing. Cytosolic. particulate and nuclear fractions of cells
were prepared as described previously (Greif et al, 1992). Equal
amounts ofprotein (20 jg.) were separated on 8% SDS-polyacryl-
amide gel and transferred to nitrocellulose (Stanwell et al. 1994).
The blots were probed for 1-2 h at room temperature with mono-
clonal antibodies specific to at. y. Y. S c. 0. T. X and isoforms
(Ono et al, 1988: Kolch et al. 1993: Wang et al, 1993; Dekkeret al;
1994) (at dilutions of 1:250 to 1:5000 in TBS-Tween buffer
containing 1% milk). Binding was detected using the appropriate
peroxidase-conjugated secondary antibody together with an
enhanced chemiluminescence kit (ECL. Amersham International).
MAPK immunocytochemistry
Monolayers ofR18 cells were fixed with 1% formnaldehyde at40C
for 90 s, followed by methanol at -200C for 10 min. and then
permeabilized with 0.1% Triton-X100 (Fisons) in phosphate-
buffered saline (PBS) for 10min. After blocking non-specific
binding sites with 10% FCS in phosphate-buffered saline (PBS),
cells were incubated for 1 h with rabbit polyclonal anti-p42
MAPK antibody (1:500) diluted in PBS/0.6% bovine serum
albumin (BSA) (Sigma), followed, after washing, by goat anti-
rabbit-TRITC antibody (1:50) (Southern Biotech) for 1 h.
Preparations were mounted in Vectashield (Vector Laboratories)
and visualized by fluorescence microscopy. Analyses were
repeated at least four times, with similar results.
Elcton microscopy
Cells were trypsinized. washed in Hank's balanced salt solution
(HBSS. Flow Laboratories), repelleted and fixed in 2.5%
glutaraldehyde diluted in Sorenson's buffer, followed by further
fixation in 2% osmium tetraoxide in acetate buffer. The fixed cell
pellet was then dehydrated in increasing ethanol concentrations
(50-100%) before embedding in araldite resin. Sections were
mounted onto standard copper grids and examined using a trans-
mission electron microscope.
Field inversion gel electophoresis (FIGE)
Cells harvested by trypsinization were pooled with cells collected
from the culture medium, pelleted by brief centrifugation at
1000 r.p.m. and then washed with PBS. Aliquots of 106 cells were
embedded into individual agarose blocks (1% LMP-agarose,
Gibco) and then incubated in0.5 M EDTA, 1% (w/v) sodium lauryl
sulphate. 4 mg ml proteinase K (Boehringer Mannheim) for48 h
at 550C. For analysis, 'digested' blocks were loaded into the wells
of a 1% FIGE gel (PFGE-certified agarose, BioRad) and sealed
with 1% LMP-agarose. The gel was run using a switching time of
3.2-32 s with a f:b ratio of 3:1 for 11 h at 150 V, stained with
ethidium bromide (10 jg ml-') and visualized on a transillumi-
nator. X Hindlil and S. cerevisiae chromosomal markers (Bio-Rad)
were included as size markers.
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Figure 2 Growth of R18 conies with mutant rasunnduced (A-D) orindiced (E-G) with tefoNlown tam ents: (A and E) uneated coro, (B and F) GF
109203X alone, (C and G) PMA alone and (D and H) simultaneous treatmt with PMA and GF 109203X
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Terminal deoxynucleotidyl transferase (TdT) assay
Attached R18 cells. grown on chamber slides. were fixed in 1%7
formaldehyde followed by 70% ethanol (-70'C) at time-points of
24. 48. 72 and 96 h after PMA treatment. Loose. detached cells
were collected from the medium at parallel time-points and fixed
in suspension in 4% formaldehyde before cytospinning onto glass
slides at a density of - 10' cells ml-'.
As positive controls. we used DoHH2 and C6 cells. in which
treatment with etoposide (VP16) has been shown to induce inter-
nucleosomal fragmentation with detection of DNA ladders and
TdT positivity after 24 h. The attached cell line. C6. was treated
with VP16 50PtM for 1 h (Malcomson et al. 1995). and attached
and loose cells were fixed as for R18. The suspended cell line.
DoHH2. was treated with VP16 0.25 p.is for 24 h and fixed as for
loose cells.
Direct TdT assay was carried out on both the cytospins and the
attached cell preparations. Briefly. the cells were rehydrated with
PBS and incubated with TdT reaction mixture [78 gl of
dH,O. 20 1 5x TdT buffer (Promega. USA). 1 gI of TdT enzyme
20 units -'1 (Promega. USA) and 1 g1 ofFITC-dUTP (Fluorogreen.
Amersham)] for 1 h (370C). After washing in PBS. cells were
mounted in Vectashield and visualized by fluorescence microscopy.
Conventional gel electrophoresis
For analysis of genomic DNA. loose. detached cells were
collected from the medium at 96 and 120 h after PMA treatment.
Untreated attached cells were trypsinized and used as a negative
control. Genomic DNA was extracted from the cell pellets using a
standard phenol extraction method (Sambrook et al. 1989). DNA.
10Aig per lane. was electrophoresed at 90 V for 3.5 h on a 1.5%
agarose/TBE gel containing ethidium bromide and was visualized
on an ultraviolet transilluminator.
RESULTS
PMA-induced cell death is mediated by stimulation,
rather than down-regulation of PKC
To distinguish an effect of stimulation from that of down-regula-
tion of PKC. we used bisindolylmaleimide (GF 109203X). a
highly selective PKC inhibitor (Toullec et al. 1990). We reasoned
that ifthe mechanism oftoxicity was via stimulation. GF 109203X
would effectively abrogate PMA-induced toxicity. whereas. if
toxicity was induced via down-regulation. GF 109203X would be
ineffective (or be toxic in itself). In addition. to account for the
possibility that GF 109203X might block toxicity by non-specific
inhibition of pathways other than those operating via PKC. we
tested the effect ofdown-regulation ofPKC by prolonged pretreat-
ment with PMA. before the induction of ras.
Effect ofinhibition ofPKC
As expected from previous work (Bond et al. 1992). infection with
a retroviral vector. t4-CRIP-DOEJ. expressing mutant H-ras
greatly extended the normally extremely limited proliferative
lifespan of primary human thyroid epithelial cells. generating an
average of40 visible colonies per 60-mm dish by 10 days (Figure
IA). Treatment with PMA. 3 days after retroviral infection. effec-
tively abolished ras-induced colony formation (Figure 1C). In
contrast. treatment with PMA together with GF 109203X resulted
in the formation of a similar number of colonies to that in
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Figure 3 Effects of 5-day treatment with PMA and/or GF 109203X on cell
growth and survival in semiconfluent cultures of R18 cells, with (filled
columns) or without (open columns) induction of mutant ras expression by
75 gm Zn2-
untreated cultures (Figure ID). as did GF 109203X alone (Figure
IB) or DMSO carrier (not shown).
When this colony growth assay was repeated using the R18
thyroid cell line in place of primary cells. similar results were
obtained. In untreated controls (with the inducible mutant ras gene
switched off). approximately 350 colonies per 60-mm dish were
obtained after 10 days. (R18 proliferation is driven by SV40 T and
is not dependent on ras.) Treatment of such uninduced cells with
PMA and/or GF 109203X had no effect on colony formation
(Figure 2A-D). Cultures in which mutant ras expression was
induced by the addition of50 ALLY Zn+ (Figure 2E) showed a slight
reduction in the number of colonies compared with uninduced
controls (Figure 2A). Addition ofPMA to cells expressing mutant
ras resulted in a striking reduction in colony yield. with only a few
small. ragged colonies surviving after 10 days (Figure 2G).
However. simultaneous exposure to GF 109203X effectively
blocked the toxic effect ofPMA. resulting in an equivalent number
ofcolonies to the untreated culture (Fioure 2H). Again. addition of
GF 109203X alone (Figure 2F) or the DMSO camer (not shown)
did not affect colony formation.
To demonstrate that the effects observed in the colony assays
reflected not only growth inhibition but also actual cell loss. an
analogous experiment was carried out using semiconfluent
cultures of RI8 cells. With mutant ras uninduced. treatment with
PMA and/or GF 109203X had little effect on cell sun'i al. cell
number increasing by approximately 20-fold offer an 8-day period
irrespective of treatment. Induction of mutant ras by 75 gM Zn>+
by itselfcaused a slight (1.3-fold) decrease in cell number (Figure
3). However. addition of PMA after ras induction resulted in
massive cell death with a tenfold decrease in cell number after
8 days in comparison with uninduced control cultures. Phase-
contrast microscopy revealed degenerative changes and cell
detachment. leaving many refractile. blebbing cells floating free in
the medium (Figure 4C). In contrast. simultaneous addition ofGF
109203X greatly reduced the magnitude of cell death induced by
PMA (Figures 3 and 4D). the cell number at 8 days not being
significantly different from those in ras-xpressing untreated
cultures (Figure 3). As observed in the other assays. treatment with
GF 109203X alone was without effect.
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Figure 4 Phase-contrast micrographs of R18 cells, atl expressing mutant ras induced by Zn2-, 5 days after thefollowing treatments: (A) untreated, (B) GF 109203X, (C) PMA and (D) PMA and GF 109203X
Effect ofdown-regulaton ofPKC
R18 cells were plated at a clonal density (3 x 103 cells per 60-mm
dish). PMA (1 g ml-') was added to one-third ofthe dishes imme-
diately upon plating ('pretreatment' dishes - set C in Figure SA),
and the cells were incubated for a period of3 days to allow down-
regulation of PKC, as previously established in our system by
measurement ofphorbol esterbinding sites (Bond et al, 1992). The
remaining plates were left in normal medium ('treatment', set B.
and 'control', set A). Zn+ (50gM) was then added to one-half of
each set of plates to induce the expression of mutant ras. After a
further period of 2 days. 1 jig ml-' PMA was added to the 'treat-
ment' plates. and all sets were assayed for the formation of
colonies after 10 days.
In the absence of ras induction. similar numbers of colonies
were found in all three conditions (Figure SB a-c). With ras
expressed (Figure SB d-f). as before. PMA abolished colony
formation (compare Figure SB d and e). However. pretreatment
with PMA greatly reduced the toxic effect of subsequent PMA
treatment (compare Figure SB e and f). although the 'protection'
was less complete than that seen with GF 109203X.
Role of specific PKC isoforms
PKC isoform expression
An array of antibodies was used to investigate the expression and
subcellular distribution ofthe conventional (a. PI.p3H.y). novel (6.
E. T1. 0) and atypical (., T and X) PKC isoforms in the R18 cell line.
Western analysis revealed expression ofa and £. together with 4. i
and A (Figure 6A). a and E being localized predominantly in the
cytoplasm. with a smaller proportion in the particulate fraction.
Expression of j . y.6 or 0 was not detectable (not shown). As 4. t
and X are atypical isoforms and not affected by PMA. this indi-
cates that the toxic effect ofPMA is mediated by activation ofone
or both ofthe remaining isoforms a and E.
Modulation ofPKC a and£ by PMA
Theroleofaand E wasexaminedfurtherby analysing the subcellular
redistribution ofthese isoforms afterexposure ofR18 cells to PMA.
In untreated cells, Western blot analysis showed PKC a to be
predominantly cytosolic with a small amount detectable in the
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Figure 5 Effect of PKC down-regulabon on PMA-induced toxicity. (A) Experinental design of te R18 cell colony assay to test the effect of PKC down-
regulation by pretreatment with PMA before induction of mutant ras. Experimental groups: set A, untreated controls: set B. standard' PMA treatment protocol:
set C. PMA pretreatment. Hatched bars indicate periods of exposure to PMA. (B) R18 colony assay to test the effect of PKC down-regulation. Growth of
colonies with mutant ras uninduced (a-c) and induced (d-f) 10 days after the treatments described in A
particulate fraction: PKC £ was more evenly distributed.
Treatment with PMA (1 jg ml-') caused a rapid shift of both
isoforms to the particulate and nuclear fractions. with little
remaining detectable in the cytoplasmic fraction by 30 min
(Figure 6B). (The faster running band in the blots of PKC a
nuclear fraction in Figure 6A and B has subsequently been shown.
using an alternative antibody. to be non-specific.)
Taken together. these results suggest that the critical biochem-
ical event in the induction of cell death is translocation of PKC a
and/or £ to membranes or nucleus.
PMA stimulates MAPK translocation: a potential
pro-apoptotic signal
The observation that PMA and mutant ras interact to bring aboutcell
death could most readily be explained on the basis of 'cross-talk
between their respective downstream signal pathways. To begin to
investigate this. we examined one candidate common pathway. the
mitogen-activated protein kinase (MAPK) cascade. which is known
to be stimulated by both PKC and ras in many cell types and which
has been associated with both proliferogenic (Marshall. 1996) and.
more recently (Kauffmann-Zeh et al. 1997). pro-apoptotic effects.
MAPK activation in the RI8 cell line was assessed indirectly by
immunocytochemistry using an anti-p42 MAPK antibody to detect
the cellular distribution of MAPK. cytoplasmic-to-nuclear trans-
location being a well-established correlate of MAPK activation
(Traverse et al. 1992; Fukuda et al. 1997). In untreated cells (mutant
ras uninduced) (Figure 7A) MAPK localization was predominantly
cytoplasmic. Surprisingly. induction of mutant ras did not produce
any detectable increase in the overall cellular content ofMAPK or in
its localization. as assessed after 2 days (Figure 7C) or earlier time-
points (not shown). In contrast PMA treatment caused a rapid redis-
tribution ofMAPK to the nucleus. very little remaining detectable in
the cytoplasm after 30 min (Figure 7B). Importantly. a similar
translocation ofindistinguishable magnitude was produced by PMA
in cells that were expressing mutant ras (Figure 7D).
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PMA and mutant rasare synergistic in inducing
apoptosis
To investigate in more detail the nature ofthe observed cell death.
RI8 cells were treated as usual with 75 pm Zn2+ for 48 h to allow
induction of mutant ras followed by PMA (1 pg ml-') and then
analysed at multiple time-points for a further 120 h.
Electron microscopy
Transmission electron microscopy ofRI8 cells expressing mutant
ras 96 h after treatment with PMA revealed condensation of
chromatin into dense patches in tight apposition to the nuclear
envelope (Figure 8A). together with ruffling and blebbing of the
plasma membrane.
FIGEanalysis
The above cultures alsodisplayed high-molecular-weight (-50 kb)
DNA fragmentation (Figure 8B) by FIGE analysis. As a positive
control. these fragments were also observed (Figure 8B) in murine
thvmocvtes treated with dexamethasone (1I( M) together with
zinc acetate (I nmm). which has been shown to prevent the final
internucleosomal cleavage stage ofapoptosis (Cohen et al. 1992).
Terminal deoxynucleotidyl transferase (TdT) assay
TdTassay was carried out both on attached cells and (when appro-
priate) on cytospin preparations ofdetached or loose cells.
Detached cells expressing mutant ras obtained from cultures
treated for 72 or96 h with PMA exhibited chromatin condensation
and numerous TdT-labelled fluorescent bodies (Figure 8C).
Interestinglv. at earlier time-points (24 and 48 h). there was
minimal detachment, with only a small proportion of these
detached cells being TdTpositive. indicating an unusually long lag
period between the trigger for apoptosis and the onset of the
.execution phase (Eamshaw. 1995). In contrast. the two positive
controls (DOHH2 and C6 cell lines treated with etoposide) both
showed strongly fluorescent. condensed chromatin and blebbing
by 24 h (data not shown). and. beyond 48 h. showed complete
degradation of DNA with TdT negativity. As expected. < 1c% of
untreated DOHH2 cells were positive.
Parallel analysis of attached R18 cells revealed very few TdT-
positi e cells. even after long periods ofPMA treatment (data not
shown). indicating that once the execution phase is initiated. cells
rapidly detach. This was also observed in the attached population
in the control cell line C6.
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Figure 6 Role of specific PKC isoforms. (A) Expression of PKC isoforms in
R18 cells. Untreated cells were homogenized and separated into cytosolic
(C), particulate (P) or nuclear (N) fractions and run on SDS-PAGE. Western
analysis was-performed using an array of specific antibodies against a, 0. ;,
£, 6. 0, 1, i and : PKC isoforms revealing expression of a and E togetherwith
i,,.. Expression ofP. y. 6 and 0 was not detectable. (B) Redistnbution of
PKC isoforms a and £ in R18 cells upon 30 min treatmentwith PMA
Conventionalgelelectrophoresis
Based on the TdT result. genomic DNA was extracted from loose
cells expressing mutant ras after 96 and 120 h of PMA treatment
andcompared with DNAextracted from trypsinized untreated R18
cells. as a negative control. Conventional gel electrophoresis
revealed internucleosomal cleavage with the production of
classical apoptotic ladders at both time-points (Figure 8D).
Taken together. these four complementary techniques provide
strong evidence to suggest that the mode ofcell death induced by
PMA in cells expressing mutant ras is apoptotic in nature.
Figure 7 Translocaton of MAPK by PMAMin R18 cells m the presence orabsence domutant raseression.Sbeuardsbuto MAPK shown by
immunofluorescence using antp2 MAPK antibody in: (A) untreated R18 cells, (B)30 min after additon of PMA, (C) cells expressing mutant ras for 2 days and
(D) 30 min after PMA treatnent ofcells already expressing mutant ras
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FigureS Evide thatteatment R18 cels mwt as with PMA induces aoptobc death. (A) E on showing (a) untreated R18
cels, (b) R18 with mant fas induced + PMA 96 h. Note pathes of conesd hoai associated with the nuclea envelope. (B) FIGE analysis of
genomic DNA for rInmolecuar-weigIt chromatin cleavage. Lanes: (a) X Iidlill, (b) BioRad S. cerevsae chrmosornal DNA markers, (c) unrelated control
cell ke (NO-tsl) genomic DNA, (d) R18 with mutant ras ixndced + PMA 96 h, (e) untreated R18 cels, (f) murine thymocytes teated with and
zinc acetate dchydrate and (g) untreated murine tynocytes. Note -50 kb frageents characteistic of apoptosis in lanes (d) and (f). (C) Teffnial
deoxysucletdYl transferase (TdT) assay of R18 cels e mutant ras + PMA 96 h. Chromatin condensation and fluorescent apoptotic bodes can be
observed in a high ppoion these loose cels colected from medani. (D) Conventional gel electrophoresis of genomic DNA for bw-molecular-weijM
internucldesomal cleavage. (a) Unreated DOHI-1H2 cells, (b) DOHI1H2 +24 h VP16 (0-25pu), (c) untreated R18, (d) R18 with mutant ras induced +96 h PMA and
(e) R18 with mutant ras induced +120 h PMA. DNA laddering can be observed at both 96 and 120 h after PMA treatment in R18 cells expressing mutant ras. A
1 -kb ladder is shown for conpanson
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DISCUSSION
Our data confirm the ability of PMA to induce cell death in both
primary and immortal thyroid cells in the presence. but not in the
absence. of mutant ras expression. We have now shown that this
cell death displays multiple characteristics of apoptosis. including
high-molecular-weight DNA fragmentation (-50 kb fragments)
and low-molecular-weight internucleosomal cleavage (-180-
200 bp fragments). The latter, however, only becomes detectable
approximately 4 days after exposure to PMA. an unexpectedly
long delay that probably accounts for its having being overlooked
in earlier work (Dawson et al. 1993). This delay suggests that a
period of gene transcription is required, possibly involving the
synthesis of essential components of the apoptotic pathway. such
as fas or fas ligand. Such a phenomenon may also explain the
apparently 'incomplete' apoptosis reported in another similar
model, the response to PMA in MCF7 breast cancer cells over-
expressing PKC a (de Vente et al. 1995).
On the assumption that conventional or novel PKC isoforms are
the crucial pharmacological target of PMA in these experiments,
there are two potential alternative mechanisms that might mediate
PMA-induced toxicity: either initial stimulation ordown-regulation
fenzyme activity (Parker et al. 1995). We have shown here that an
inhibitor of c and n PKCs. GF 109303X (Toullec et al. 1990). effec-
ively abolishes the toxic effect of PMA in both primary cultures
md the cell line model. This strongly suggests that it is the initial
Stimulation of PKC by PMA that induces toxicity, because, if this
was a result ofdown-regulation. inhibition ofPKC by GF 109203X
would be expected to mimic, not inhibit, PMA-induced cell death.
The finding that down-regulation of PKC by pretreatment with
?MA is also protective provides further support for this conclusion
nd argues against the possibility that GF 109203X abrogates
oxicity by a mechanism independent of PKC.
It should be noted that the failure of GF 109203X to prevent H-
-as-induced mitogenesis in primary thyroid epithelial cells demon-
trates that this response to ras is independent of conventional or
ovel PKC isoforms. although we cannot exclude the possible
nvolvement of an atypical PKC, such as 4. which has been shown
o play a role in ras-induced mitogenic signalling in some other
nodels. e.g. oocytes and NIH 3T3 fibroblasts (Berra et al, 1993).
Western blot analysis showed the presence ofPKCs E l. and
. As t.X and 4are atypical isoforms and not affected by PMA.they
'an be eliminated as potential candidates, suggesting that a and/or
are the critical isofonrns for the induction ofcell death. Consistent
vith this. Western analysis showed that a 30-min treatment with
"MA induced translocation of PKC a and £ from the cytoplasm
o the particulate and nuclear fractions. Further discrimination
between a and E was not attempted here but may be possible
hrough use of isotype-specific constitutively active mutants
Schonwasser et al. 1998) or through differential down-regulation
of one isoform by lower concentrations of PMA (Cai et al. 1997).
tesults from other models suggest that a and E may function as
Iternative (redundant) signalling pathways (Cai et al. 1997).
The most obvious downstream target for PKC in this system is
he MAPK pathway. PKC a (Kolch et al. 1993) and £ (Cai et al.
997) have been shown to activate rafleading to subsequent activa-
ion of MAPK (Marquardt et al. 1994), although the exact mecha-
ism (in particular the role of phosphorylation) is still disputed
Schonwasser et al. 1998). There is also evidence for raf-indepen-
ent activation through alternative MEK kinases (Chao et al, 1994)
r even at the level of MAPK itself (Grammer and Blenis. 1997).
Furthermore. MAPK activation has been associated with apoptosis
in several (although by no means all) cell models (Xia et al. 1995:
Fukasawa and Vande Woude. 1997: Kauffmann-Zeh et al. 1997).
MAPK would also be expected to be activated by mutant ras.
however. raising the possibility that PMA would not be able to
produce any further increase in activity in mutant ras-expressing
cells. The observation that PMA can still induce nuclear transloca-
tion of MAPK. a well-established (although admittedly indirect)
index of MAPK activation (Fukuda et al. 1997). even in the pres-
ence ofmutant ras. is therefore important in supporting the role of
this pathway in PMA-mediated cell death.
The major mechanistic question raised by our data. however. is
why thyroid cells are only killed by PMA in the presence of
mutant ras. Although originally regarded as anti-apoptotic. it is
now clear that ras activation in itself can generate anti- or pro-
apoptotic effects. depending on the context (Lin et al. 1995:
Fukasawa et al, 1997: Kauffmann-Zeh et al. 1997). In one well-
characterized model (Kauffmann-Zeh et al. 1997). for example.
use ofraseffectormutants showed that the outcome can depend on
the balance between ras signalling pathways. in this case P13K
being anti-apoptotic with MAPK and/orJNK being pro-apoptotic.
MAPK is an attractive candidate as it is the obvious point of
convergence between ras and PMA. and we have previously
postulated that the 'sensitizing' effect ofmutant ras might operate
by a simple additive interaction between ras and PMA on MAPK
signalling, resulting in an excessive and therefore pro-apoptotic
signal. Although this is not supported by the MAPK translocation
data. which show no discernible difference between the MAPK
response to PMA in the presence or absence of mutant ras. this
cannot be regarded as conclusive. as translocation is an indirect
index ofactivation. and it would be rather surprising ifexpression
of mutant ras alone failed to result in any degree of sustained
activation. It remains formally possible therefore that more
direct analysis by assessment of MAPK phosphorylation status
and in vitro kinase activity may still reveal such an additive
interaction. Nevertheless, we clearly need to consider the alterna-
tive possibility that the sensitizing effect of ras operates via a
different pathway. for which the MEKKISAPKK/JNK cascade
must currently be the strongest candidate (Xia et al. 1995: Johnson
etal. 1996).
Distinction between these alternatives should be possible by
direct manipulation ofthe MAPKorJNK pathways using constitu-
tively active or dominant-negative mutants (Cowley et al. 1994).
pharmacological inhibitors (Alessi et al. 1995; Cohen. 1997) or
ras effector mutants (Kauffrnann-Zeh et al. 1997). Whatever the
outcome.the model that is emerging is that signals generated in the
thyroid cell by mutant ras are in a state ofdelicate balance that is
tipped in favourofapoptosis by the additional pro-apoptotic effect
ofPMA. mediated most probably via MAPK.
Experiments using a wide range ofcell types have demonstrated
either cytostatic or cytotoxic effects of supraphysiological ras
signalling (Franza et al, 1986; Hirakawa and Ruley. 1988: Ridley
et al. 1988). most recently in human fibroblasts (Serrano et al.
1997). In these models.however.cells were effectively rescued by
loss ofeither the p53-and/or the pRb-mediated signal pathways. In
contrast, in the human cell system described here, abrogation of
both functions by SV40T (which is expressed by both R18 and its
parent line) does not appear to protect against PKC-induced cell
death in the presence of mutant ras. This is potentially of thera-
peutic significance. as it suggests that PKC stimulators would be
effective even against tumoursthat had lost p53 function.
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Given the high frequencv of ras mutations in many tumour
types. the specificity of PMA-induced toxicity for thyroid epithe-
lial cells expressing mutant ras increases the interest in PKC as an
intracellular target for therapy.
On a purely empirical basis. one potent PKC activator. bryostatin
1. has already been shown to exert cytostatic or cytotoxic effects
ainst some types ofcancer cells both in vitro and in vivo (Gescher.
1992: Hornung et al. 1993) and has shown sufficient promise to be
taken into clinical trials for treatment of melanoma and leukaemia
(Philips et al. 1993: Prendiville et al. 1993). Unfortunately. however.
in our model. brvostatin appears to be much less effective than PMA
at all doses tested (Dawson et al. 1993).
One major biological property of PMA. not shared by bryo-
statin. is the ability to promote mutagen-induced experimental
skin turnours (Hennings et al. 1987). related probably to its ability
to induce keratinocvte differentiation (Szallasi et al. 1994). This
raises the possibility that the cytotoxic effect of PMA against
mutant ras-expressing cells might be inextricably linked to its
tumour-promoting activity. Nevertheless. the pharmacological
difference between brvostatin and PMA that most closely corre-
lates with their different tumour-promoting properties is the
inability of bryostatin to down-regulate PKC-6 (Szallasi et al.
1994). This difference is consistent with the suspected importance
of chronic down-regulation rather than acute activation of PKC in
tumour promotion by phorbol esters (Blumberg. 1991: Droms and
Malkinson. 1991). Our model. however. depends solely on stimu-
lation of PKC isoforms. and the lack of potency of bryostatin
compared with PMA here is therefore more likely to be related to
differences in its ability to stimulate PKC. such as the slower
kinetics of PKC cc and £ stimulation observed in keratinocytes
(Szallasi et al. 1994). This is important for future work. as it
supports the feasibility of designing an agent that would be as
effective as PMA in killing cells expressing mutant ras but without
its tumour-promoting properties.
Even if such an ideal agent was unavailable. however. the thera-
peutic potential of phorbol esters should not be written off simplN
on the historical basis ofexperimental skin tumour promotion. As
mentioned above. there is much evidence to sugaest that this
results from long-term down-regulation of PKC (Blumberg. 1991:
Droms and Malkinson. 1991). whereas the potential tumoricidal
action reported here is an acute response dependent on short-term
stimulation of PKC and should therefore require only 'bolus'
administration. There is no evidence that such use would lead to
increased risk of second tumours. and our preliminary toxicolog-
ical studies in rats have shown no obvious signs of acute toxicity
after systemic administration ofphorbol esters.
Therapeutic use of such agents may therefore be a much more
realistic option than might appear at first sight. Although the range
of susceptible epithelial cell types has not yet been explored. an
obvious target would be pancreatic cancer. which has a very hiah
ras mutation rate and which currently carries a dismal prognosis.
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